S03 Dogma Disrupting Therapeutic Strategies to Combat Endocrine Resistant Cancers

Program: Symposia
Basic/Translational Session
Friday, April 1, 2016: 9:45 AM-11:15 AM
Room 258 (BCEC)
Steven Paul Balk, MD, PHD, Beth Israel Deaconess Med Ctr, Boston, MA

Nothing to Disclose: SPB
9:45 AM
David J Shapiro, PhD, Dept of Biochemistry, University of Illinois, Urbana, IL
Nothing to Disclose: DJS
10:15 AM
Alexandra C Newton, PhD, Pharmacology, University of California at San Diego
Nothing to Disclose: ACN
10:45 AM
Ruth Ann Keri, PhD, Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH
Nothing to Disclose: RAK
See more of: Symposia


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire